Auransa Joins Forces with Singapore’s Experimental Drug Development Centre to Discover New Therapies for COVID-19 and Other Coronavirus Pandemics

The collaboration will fast track research by combining predictive AI with molecular data to discover new therapeutic strategies for viral pandemics

PALO ALTO, California / September 29, 2020Auransa, Inc., an artificial intelligence (AI)-driven pharmaceutical company, today announces a research collaboration around drug discovery to fight COVID-19 and coronaviruses in general, with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development.

The partnership brings together two organizations with complementary expertise and a shared goal of improved pandemic response. Auransa’s proprietary predictive computational platform, SMarTR™ Engine, leverages machine learning, advanced analytics, and mathematics in an AI framework to generate insights from molecular data on the disease biology and patient subtypes. 

EDDC possesses a full range of drug discovery capabilities, including assay development, high throughput screening, antibody cloning, medicinal chemistry, and ADME/toxicology. These capabilities allow EDDC to identify drug hits and leads, and develop them to the preclinical candidate stage in-house.

There is wide recognition of the need for medicines to treat COVID-19 patients in the absence of a vaccine or the lack of adequate immune response to vaccines. The collaboration will address this challenge with therapeutics that disrupt the replication machinery of the novel coronavirus. This will help patients to fight the effects of the virus, thereby limiting the severity of current and future viral pandemics on patients and healthcare infrastructures.

“We are excited to work with EDDC and use our AI engine to support the fight against coronaviruses. Therapeutics play a vital role in controlling the impact of any pandemic, even when a vaccine is present. We believe this collaboration with EDDC, an institute that is highly regarded as a leader of drug discovery and development in Singapore, will allow us to reach that goal,” stated Pek Lum, Ph.D., chief executive officer of Auransa.

Professor Damian O'Connell, chief executive officer of EDDC, Agency for Science, Technology and Research (A*STAR), said: “This research collaboration leverages advanced technologies to develop therapeutic strategies against the virus causing COVID-19. We are pleased to combine EDDC’s drug discovery and development capabilities with Auransa’s innovative AI platform to contribute to the fight against coronaviruses in the current pandemic and beyond.”

About Auransa

Auransa is an artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet medical need.  The company is working to redefine precision medicine by combining a sophisticated, proprietary, and predictive computational platform with traditional pharmaceutical industry experience.  The company’s SMarTR™ Engine has proprietary machine learning, advanced analytics, and mathematics in an AI framework to generate insights from molecular data for a deep understanding of disease biology and patient subtypes. The company has successfully generated a broad pipeline of drug candidates including programs addressing cancer, auto-immune, infectious, and metabolic diseases that are advancing toward investigational new drug (IND) filings.  For more information, please visit

To read more Press Release articles, click here.